DBV Technologies - ADR

-0.03 (-2.17%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)253.51M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.42 Million
Adjusted EPS-$0.22
See more estimates
10-Day MA$1.41
50-Day MA$1.40
200-Day MA$1.80
See more pivots

DBV Technologies - ADR Stock, NASDAQ:DBVT

177-181, avenue Pierre Brossolette, 177-181, avenue Pierre Brossolette, Montrouge, Ile-de-France 92120
Phone: +
Number of Employees: 92


DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, St?©phane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.